CASP3 and bladder transitional cell carcinoma: In conclusion, our study demonstrated that the combination treatment of DAC plus ENT is cancer-selective and highly synergistic in inhibiting the proliferation of urothelial bladder cancer cells via induction of apoptosis and caspase 3/7 activation.